What is it about?

Recent innovative non-pharmacological interventions and neurostimulation devices have shown potential for application in the treatment of Alzheimer’s disease. These include photobiomodulation therapy. This randomized control trial assesses a brain-gut photobiomodulation therapy for Alzheimer’s disease patients.

Featured Image

Why is it important?

This is the first randomized controlled trial in Alzheimer's disease evaluating the first medical device that targets the brain-gut axis. The brain-gut photobiomodulation therapy proved to be safe. The majority of the patients were highly compliant. Despite its reduced statistical power due in part to the premature study termination related to the COVID-19 pandemic, this study also highlights encouraging efficacy trends on certain outcomes.


The present study provides valuable insights for the design of the next phase trial, which will address the cognitive benefits of the brain-gut photobiomodulation therapy in a larger sample of Alzheimer’s disease patients. This pivotal trial could demonstrate that REGEnLIFE’s brain-gut photobiomodulation device could be a safe, well-tolerated and efficient treatment for mild-to-moderate Alzheimer’s disease patients, with medical and economic benefits.

Guillaume Blivet

Read the Original

This page is a summary of: A Randomized, Double-Blind, and Sham-Controlled Trial of an Innovative Brain-Gut Photobiomodulation Therapy: Safety and Patient Compliance, Journal of Alzheimer s Disease, November 2022, IOS Press,
DOI: 10.3233/jad-220467.
You can read the full text:




The following have contributed to this page